CClinicalTrials.gg
RecruitingNCT06302205PHOENIX-LUpdated Apr 1, 2024

A Home-based Exercise and Physical Activity Intervention After Liver Transplantation: Impact of Exercise Intensity

An interventional study of Physical activity and Sham intervention in Liver Transplantation and Physical Fitness, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-01.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as recruiting.
  • Registered 9 months after the study started (first participant enrolled Mar 2023, registered Dec 2023).
  • Started Mar 2023; still recruiting 3 years 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Research demonstrated that transplant recipients benefit from physical activity, but there is a gap in knowledge regarding the required intensity. In the PHOENIX-Liver study, researchers aim to investigate the adequate intensity of rehabilitation programs after liver transplantation. Patients will be randomized into one of the three PHOENIX-Liver training groups (low, moderate, moderate to high). The six months rehabilitation program is conducted from the patient's home but supervised by a PHOENIX-investigator.

At baseline, after three months of rehabilitation and after six months of rehabilitation, a test moment takes place at which physical fitness, cardiovascular health, liver function, and body composition will be assessed. Questionnaires are taken monthly to survey well-being, safety, quality of life, physical activity, and cost-effectiveness.

To gather information on the potential for implementation in a real-world setting, a 15-month-long physical activity phase will start after the intervention phase. This entails a maintenance physical activity program tailored to the patients' preferences. A follow-up at UZ Leuven is planned at three and at 15 months where the same clinical evaluations will be conducted as during the test moments of the intervention phase.

Read the detailed description

Liver transplantation constitutes the only curative treatment for patients with end-stage liver disease. Advances in the field have led to favourable short- and medium term (1-3 year) post-transplant survival rates, but improvement in long-term survival rates remains disappointing. Due to the immunosuppressive therapy, a sedentary lifestyle and a poor recovery of post-transplant physical fitness, the proportion of liver transplant recipients that develop a new-onset or a deteriorating unfavourable cardiovascular risk profile is alarmingly high, and cardiovascular disease is the leading cause of death in this population. By consequence, in order to improve long-term outcome after liver transplantation, prevention of cardiovascular disease should be prioritized. The investigators are convinced that the challenge of cardiovascular disease and lack of physical fitness in liver transplant recipients should and can be addressed by subjecting these patients to a structured physical rehabilitation program. The aim of this project is implement a structured, individually-tailored, home-based but supervised physical rehabilitation and maintenance program for de novo liver transplantation recipients, and to demonstrate the feasibility and safety of such approach as well as its efficacy to improve physical fitness. The program will consist of a 2-phase intervention of i) home-based exercise training (aerobic exercise training as well as strength, flexibility and stability exercises under in-person and subsequently remote guidance) and ii) an 15-month maintenance phase of physical activity. This program will be studied in an open-label randomized trial where the regimen will be compared with a regimen of standard of posttransplant care. In addition to the interventional arm, two different regimens of exercise training intensity will also be studied.

02

Conditions studied

  • Liver Transplantation
  • Physical Fitness

Keywords

  • Exercise Intensity
03

In context

Lead sponsor

Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 928 studies on the registry; 261 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • de novo adult liver transplant recipients with a transplant vintage of two to three months
  • access to a home freezer (± -18°C)

Exclusion criteria

Exclusion Criteria:

  • Aberrant CPET (abnormal low cardiorespiratory fitness is not considered an exclusion criteria), unstable angina, life-threatening arrhythmias, uncontrolled hypertension/diabetes, HbA1c ≥ 9%, severe pulmonary disease (FEV1 \< 50%), musculoskeletal disorders not allowing physical training on a cycle ergometer, or any other medical reasons by the physician considered to be a contraindication for moderate or high-intensity physical exercise
  • multi-organ transplantation (exception: combined liver-kidney transplant is considered eligible for participation)
  • ongoing treatment for malignancies
  • unable to understand Dutch
  • no access to smartphone and/or computer with internet access
  • does not willing to except the general conditions of Coachbox. Preparticipation medical screening (cardiopulmonary exercise testing with 12-lead ECG + stratification of cardiovascular risk factors) will be performed by a cardiologist (Dr. Kaatje Goetschalckx at UZ Leuven).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
147 participants (estimated)

Study arms

  • Sham comparator
    Sham Group

    Home-based low-intensity exercise training without subsequent physical activity intervention.

    Other: Sham intervention

  • Experimental
    Moderate-intensity (MIT)

    Home-based moderate-intensity exercise training with subsequent physical activity intervention.

    Other: Physical activity

  • Experimental
    Combined moderate and high-intensity (MHIT)

    Home-based moderate- and high-intensity exercise training with subsequent physical activity intervention.

    Other: Physical activity

Interventions

  • OtherPhysical activity

    The home-based training intervention consists of two phases of each three months in duration. It consists of three weekly aerobic training sessions on the one hand, and two weekly training sessions focused on strength, balance, and flexibility on the other hand.

  • OtherSham intervention

    2 times a week, flexibility and balance training

06

What researchers measure

Primary outcomes

  1. Cardiorespiratory fitness

    Changes in peak oxygen uptake (mL O2·min-1·kg-1) assessed by cardiopulmonary exercise test

    Time frame: At 0, 3 and 6 months of the interventional rehabilitation programme and at 15 months after the end of the intervention

Secondary outcomes

  1. Functional exercise capacitiy

    six-minute walking test (m)

    Time frame: At 0, 3 and 6 months of the interventional rehabilitation programme and 15 months after the end of the intervention

  2. Hand grip strength

    assessement by means of Jamar Hydraulic Hand Dynamometry (kg)

    Time frame: At 0, 3 and 6 months of the interventional rehabilitation programme and 15 months after the end of the intervention

  3. Knee-extensor strength

    assessement by means of Biodex dynamometer (Nm)

    Time frame: At 0, 3 and 6 months of the interventional rehabilitation programme and 15 months after the end of the intervention

  4. Endothelial function

    assessed via flow mediated dilation

    Time frame: At 0, 3 and 6 months of the interventional rehabilitation programme and 15 months after the end of the intervention

  5. Arterial stiffness

    assessed via pulse wave velocity

    Time frame: At 0, 3 and 6 months of the interventional rehabilitation programme and 15 months after the end of the intervention

  6. Graft function

    Transient elastography Fibroscan assessing liver stiffness

    Time frame: At 0 and after 21 months

  7. Occurence of adverse events

    Safety is estimated by means of questionnaires

    Time frame: Monthly

  8. Motor fitness

    Short Physical Performance Battery test

    Time frame: At 0, 3 and 6 months of the interventional rehabilitation programme and 15 months after the end of the intervention

  9. Blood pressure

    Variation in blood pressure measured by means of automatic device (Omron M6) in fasted condition and without medication taken in

    Time frame: At 0, 3 and 6 months of the interventional rehabilitation programme and 15 months after the end of the intervention

  10. Blood profile

    Blood is drawn when patient is in fasted condition and did not take their medication

    Time frame: At 0, 3 and 6 months of the interventional rehabilitation programme, and at 3 and 15 months after the end of the intervention

07

Study locations

1 of 1 sites recruiting
  • UZ Leuven
    Leuven, Vlaams-Brabant 3000, Belgium
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06302205
Lead sponsor
Universitaire Ziekenhuizen KU Leuven
Collaborators
KU Leuven
Responsible party
Sponsor
First posted
Mar 8, 2024
Start date
Mar 1, 2023
Primary completion
Jan 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 1, 2024

Study contacts

Diethard Monbaliu, MD PhD
Contact
diethard.monbaliu@uzleuven.be
+3216342361
Stefan De Smet, PhD
Contact
stefan.desmet@kuleuven.be

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion